Bannerbild German Brest Group - Newsroom

Newsroom der German Breast Group

In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.

 
  • 31.08.2018 Paper of the month: Endocrine Therapy in HEGR2 neg mBC

    A review that summarized the available data on endocrine therapy for premenopausal women with HER2-negative hormone receptor-positive metastatic breast cancer (MBC) has been published in the Oncologist.

  • 28.08.2018 GBG 79 BrainMet (BMBC): erste Daten publiziert

    Die erste Analyse der BMBC-Registerstudie zur Versorgung von Patientinnen mit Hirnmetastasen wurde im European Journal of Cancer veröffentlicht.

  • 24.08.2018 ASCO Trending: GeparNuevo

    ASCO Trending: GeparNuevo

    Priming the Immune System: Neoadjuvant Durvalumab Plus Chemotherapy May Be Beneficial in Triple-Negative Breast Cancer

  • 31.07.2018 Paper of the month: BRCA1/2 Mutations and Bevacizumab

    A translational research study performed with samples obtained from a cohort of patients with triple-negative breast cancer (TNBC) enrolled in the neoadjuvant GeparQuinto (GBG 44) study has been published in the Journal of Clinical Oncology.

  • 06.07.2018 Review on Endocrine Therapy in Premenopausal HR+/HER2- Metastatic Breast Cancer

    Unser Review zur Endokrine Therapie in prämenopausale Patientinnen mit Hormone Rezeptor-positivem, HER2-negativem metastasiertem Brust Krebs wurde in The Oncologist publiziert.

  • 30.06.2018 Paper of the month: test predicts the risk of recurrence in luminal breast cancer

    A translational study including samples from two randomized neoadjuvant GBG trials (GeparTrio and GeparQuattro) that aimed to evaluate a novel test (mEPclin) for predicting the risk of distance recurrence after neoadjuvant chemotherapy in patients with residual estrogen receptor (ER)-positive/HER2-negative breast cancer has been published in the Clinical Cancer Research.

  • 04.06.2018 ASCO: GeparNuevo Presentation

    GeparNuevo Results of primary objective were presented at ASCO 2018: Durvalumab increases the pCR rate in TNBC patients.

  • 31.05.2018 Paper of the month: elderly women and neoadjuvant chemotherapy

    A pooled analysis using data from eight GBG trials (GeparDuo, GeparTrio pilot and main, GeparQuattro, AGO-1, PREPARE, TECHNO; GeparQuinto) that aimed to help selecting appropriately the elderly women who would benefit from neoadjuvant chemotherapy has been published in the Oncotarget.

  • 30.04.2018 Paper of the month: survival analysis of the GeparQuinto trial

    We are delighted to inform you that the long-term survival analysis of the neoadjuvant GeparQuinto (GBG 44) phase III trial has been published in the Journal of Clinical Oncology.

  • 30.03.2018 Paper of the month: March 2018

    An analysis of 802 women with triple-negative breast cancer (TNBC) from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) and GeparSixto (GBG 66) trial that investigated the association between the age at TNBC diagnosis and the presence of pathogenic germline BRCA1/2 mutations has been published in the BMC Cancer.

  • 13.03.2018 ESMO 2019

    ESMO 2019

    ESMO Breast Cancer congress ist taking place in May 2019 in Berlin, Germany.

  • 28.02.2018 Paper of the month: February 2018

    The first results of the BrighTNess trial designed to evaluate the addition of veliparib (a PARP inhibitor) plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) have been published in the The Lancet Oncology.

  • 02.02.2018 Informationsvideo für Patienten

    Prof. Loibl, Leiterin der GBG und Prof. Jackisch, Chefarzt am Sana Klinikum Offenbach sprechen mit einer Patientin über ihre Erfahrungen in einer klinischen Studie.

  • 31.01.2018 Paper of the month: January 2018

    A collaborative translational study that included data from six neoadjuvant GBG trials (GeparDuo, GeparTrio, GeparQuattro, GeparQuinto, GeparSixto and GeparSepto) and investigated the role of tumour-infiltrating lymphocytes (TILs) as a prognostic factor in different subtypes of breast cancer after neoadjuvant therapy has been published in the The Lancet Oncology.

  • 22.01.2018 JCO top-cited

    Unser Paper über PIK3CA-Mutationen ist eines der meistzitierten Paper in JCO.

  • 12.01.2018 Neue Anforderungen für GCP-Nachweise

    Ab Januar 2018 verlangen viele Ethikkommissionen GCP-Nachweise mit neuen Anforderungen.

  • 04.12.2017 Mamma Mia! Patientenkongress in Frankfurt

    Mamma Mia! Patientenkongress am 4. Februar 2018 (Weltkrebstag) im Kap Europa, Frankfurt/M.

  • 17.08.2017 Effect of BRCA1/2 Status on Response to Neoadjuvant Carboplatin in TNBC

    Unser Paper zur Mutationsanalyse im Geparsixto-TNBC-Arm wurde in den ASCO-News besprochen.

  • 05.07.2017 PALOMA-3 Results published

    Palbociclib Combined with Fulvestrant in PremenopausalWomen with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results

  • 13.04.2017 Gewinner des Young Investigator Award

    Gewinner des Young Investigator Award

    Wir gratulieren dem Gewinner des Young Investigator Award 2017, Dr. med. André Hennigs aus Heidelberg

Kontakt

GBG Forschungs GmbH

+49-61027480-0

+49-61027480-440

E-Mail: nfgbgd



GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd